Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04950615 versus placebo in high-risk primary hyperlipidemia or mixed dyslipidemia
NL-OMON42129Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial hyperlipidemia and combined dyslipidaemia comparing PF-04950615 + background statin with Placebo + background statin (2 arms). Started Mar 2015; status: active, not recruiting.
02
Drugs
bococizumab
03
Conditions
familial hyperlipidemiacombined dyslipidaemia
Beyond the preview
Go deeper on NL-OMON42129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42129.